Healthcare provider profile · identity verified

Ryan M Heffelfinger, DO

Family Practice · WINDSOR, CT · NPI 1831293570

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	494	141
Amlodipine Besylate	Amlodipine Besylate	396	119
Levothyroxine Sodium	Levothyroxine Sodium	235	63
Rosuvastatin Calcium	Rosuvastatin Calcium	234	71
Lisinopril	Lisinopril	153	46
Tamsulosin Hcl	Tamsulosin Hcl	142	41
Losartan Potassium	Losartan Potassium	139	41
Metformin Hcl	Metformin Hcl	133	37
Lorazepam	Lorazepam	132	33
Olmesartan Medoxomil	Olmesartan Medoxomil	128	36
Omeprazole	Omeprazole	126	40
Tramadol Hcl	Tramadol Hcl	125	26
Metformin Hcl Er	Metformin Hcl	118	35
Simvastatin	Simvastatin	115	34
Hydrochlorothiazide	Hydrochlorothiazide	109	34
Metoprolol Succinate	Metoprolol Succinate	107	32
Gabapentin	Gabapentin	105	30
Albuterol Sulfate Hfa	Albuterol Sulfate	98	34
Pantoprazole Sodium	Pantoprazole Sodium	94	27
Alprazolam	Alprazolam	92	22
Escitalopram Oxalate	Escitalopram Oxalate	88	29
Ozempic	Semaglutide	83	14
Eliquis	Apixaban	79	21
Allopurinol	Allopurinol	64	18
Glipizide Er	Glipizide	64	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	63	21
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	63	18
Trazodone Hcl	Trazodone Hcl	60	22
Fluticasone Propionate	Fluticasone Propionate	58	24
Duloxetine Hcl	Duloxetine Hcl	56	17
Chlorthalidone	Chlorthalidone	51	13
Sertraline Hcl	Sertraline Hcl	48	15
Atenolol	Atenolol	46	12
Zolpidem Tartrate	Zolpidem Tartrate	46	14
Jardiance	Empagliflozin	45	17
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	44	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	13
Metoprolol Tartrate	Metoprolol Tartrate	44	15
Clonazepam	Clonazepam	43	13
Pioglitazone Hcl	Pioglitazone Hcl	43	11
Potassium Chloride	Potassium Chloride	43	14
Famotidine	Famotidine	42	18
Montelukast Sodium	Montelukast Sodium	42	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	41	11
Celecoxib	Celecoxib	40	11
Spironolactone	Spironolactone	40	14
Carvedilol	Carvedilol	37	13
Furosemide	Furosemide	35	13
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	34	suppressed
Pregabalin	Pregabalin	34	suppressed
Lovastatin	Lovastatin	33	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Ipratropium Bromide	Ipratropium Bromide	32	suppressed
Valsartan	Valsartan	32	11
Ezetimibe	Ezetimibe	31	suppressed
Ibuprofen	Ibuprofen	31	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	30	suppressed
Donepezil Hcl	Donepezil Hcl	30	suppressed
Propranolol Hcl Er	Propranolol Hcl	29	suppressed
Cephalexin	Cephalexin	27	21
Alendronate Sodium	Alendronate Sodium	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Meloxicam	Meloxicam	26	12
Mirtazapine	Mirtazapine	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	13
Wixela Inhub	Fluticasone Propion/Salmeterol	25	12
Finasteride	Finasteride	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Prednisone	Prednisone	23	22
Synthroid	Levothyroxine Sodium	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	21	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	20	suppressed
Azithromycin	Azithromycin	20	20
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	14
Xarelto	Rivaroxaban	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	17
Farxiga	Dapagliflozin Propanediol	18	suppressed
Folic Acid	Folic Acid	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Risperidone	Risperidone	13	suppressed
Butalbital-Aspirin-Caffeine	Butalbital/Aspirin/Caffeine	12	suppressed
Desloratadine	Desloratadine	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error